Inspire Medical Systems (INSP) Stock May Be A Bargain On Raised 2026 Guidance
Inspire Medical Systems stock is coming off a sharp three year share price decline, yet the current valuation checks paint a more balanced picture. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares are roughly in line with fair value, and the earnings and revenue multiples lean toward undervalued.
- The share price has fallen 78.7% over the past three years, which puts a heavy focus on whether the current level fairly reflects Inspire Medical Systems' long term cash flow potential.
- Recent revenue outperformance against expectations and a new cost focused growth plan can support higher value if execution holds, while the associated restructuring charges and any pressure on near term earnings may weigh on how much investors are willing to pay today.
- On Simply Wall St's broader checks, Inspire Medical Systems scores 4 out of 6 on valuation, which points to a mixed picture rather than a clear bargain or clear overvaluation.
For investors, the debate is whether the recent repricing leaves Inspire Medical Systems attractively valued for a possible recovery in fundamentals or already close to its intrinsic value estimate.
Find out why Inspire Medical Systems' -40.6% return over the last year is lagging behind its peers.
Where Does Inspire Medical Systems Sit on Cash Flow?
The Discounted Cash Flow (DCF) model values Inspire Medical Systems by projecting its future free cash flows and discounting them back to today. On this measure, the company produced about $95.9 million in free cash flow over the latest twelve months, and the forecast path assumes cash flows that grow for a period then ease back toward a more mature level. That pattern feeds into an estimated intrinsic value of about $56 per share.
This DCF output implies the stock trades at roughly a 7.0% discount to that intrinsic value, so it screens close to fairly priced rather than markedly cheap or expensive. Because Project Horizon involves restructuring charges in the near term, the recent plan helps explain why the share price may still sit below the model value despite raised 2026 guidance.
On balance, Inspire Medical Systems screens as roughly fairly valued on a cash flow basis, with only a modest discount to the DCF estimate.
Inspire Medical Systems is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Is Inspire Medical Systems Still Cheap on Earnings?
The P/E ratio fits Inspire Medical Systems well because earnings are already positive and used in guidance. Right now the stock trades on about 11.5x earnings, which sits below the wider medical equipment industry average of 29.9x and also below the peer group average of 94.8x.
On Simply Wall St’s fair P/E estimate, which adjusts for Inspire Medical Systems' size, business profile and risk, a ratio of about 15.2x would be in line with expectations. That is higher than the current 11.5x, so the shares appear inexpensive on this yardstick even after the recent post-results rebound.
On the P/E multiple, Inspire Medical Systems stock appears undervalued relative to what the tailored fair ratio suggests.
See what the numbers say about this price — find out in our valuation breakdown.
The Inspire Medical Systems Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Inspire Medical Systems act as the missing link between the mixed valuation picture above and the real world assumptions that would need to play out on growth, margins and earnings for the stock to be worth materially more or less than today’s price. These Narratives sit on the company’s Community page. Instead of stopping at a single output from a model or ratio, they spell out the future that figure relies on so you can watch how the actual business compares over time.
The community is split on Inspire Medical Systems, with one camp seeing the current price as an entry into a mispriced growth story and the other focused on coding and reimbursement risks.
Bull case: 19% undervalued
"The anticipated publication of the PREDICTOR clinical evidence, which could broadly eliminate the need for DISE in patient selection, will meaningfully expand Inspire's total treatable OSA population..."
Read the full Bull Case to see why Inspire Medical Systems could be undervalued
Bear case: 34% overvalued
"The effective addressable market for Inspire's device may be threatened by the increasing preference for non-invasive or at-home solutions for obstructive sleep apnea, such as next-generation CPAP devices or drug therapies..."
Read the full Bear Case to see why Inspire Medical Systems could be overvalued
Do you think there's more to the story for Inspire Medical Systems? Head over to our Community to see what others are saying!
The Bottom Line
Inspire Medical Systems screens as roughly fairly valued on a Discounted Cash Flow (DCF) view, with only a small discount to the intrinsic value estimate, while the P/E comparison still points to an undervalued stock versus both industry and tailored fair ratios. The broader checks are mixed rather than clearly cheap, so the gap between models mainly comes down to how much weight you put on future cash flow delivery versus the potential for the earnings multiple to catch up. The key question from here is whether Inspire Medical Systems can execute its cost focused plan without denting growth in a way that would justify the current discount as a value trap instead of an opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com